GlobalData found that Oncology was the largest therapy area for clinical trials in...
August’s top news stories
Gradalis started a Phase lll clinical trial of Vigil in combination with irinotecan and temozolomide for the treatment of patients with Ewing’s sarcoma, and Impel NeuroPharma dosed the first subject in the Phase l Safety and Tolerability of Intranasal POD-olanzapine (SNAP 101) trial of INP105. Drugdevelopment-technology.com wraps up the key news stories from August 2018.
Detecting the Presence of Trace Polymorphs and Impurities
In the pharmaceutical industry, the detection of polymorph traces is one of the most important applications of powder x-ray diffraction (PXRD).
July’s top news stories
The Kyoto University’s Centre for iPS Cell Research and Application (CiRA) in Japan is to start two clinical trials that will evaluate human induced pluripotent stem cells (iPS) to treat Parkinson’s disease, and Critical Path Institute’s (C-Path) Critical Path for Parkinson’s Consortium (CPP), along with Parkinson’s UK, announced that the European Medicines Agency (EMA) issued a positive qualification opinion on biomarker as a tool to boost clinical trials on Parkinson’s. Drugdevelopment-technology.com wraps up the key news stories from July 2018.
Virus Development and Production: Measuring with MADLS
For virus development and production, it is important to know the virus concentration at different stages of the process, to optimise the clone used and the production yields.
Getting Acquainted with the Theory of XRF
This white paper provides a general introduction to X-ray Fluorescence (CRF) spectrometry and XRF analysis. It explains how a spectrometer works and how XRF analysis is achieved.
JYNARQUE™ (tolvaptan) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
JYNARQUE™ (tolvaptan) is indicated for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
June’s top news stories
Servier and Galapagos commenced the ROCCELLA Phase 2 clinical trial to evaluate the efficacy and safety of S201086/GLPG1972 to treat patients with knee osteoarthritis (OA); and Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company reported positive top-line results from the EASE trial programme. Drugdevelopment-technology.com wraps up the key news stories from June 2018.
Zepatier for the Treatment of Chronic Hepatitis C Genotype 1 and 4 Infection
Zepatier is a once-daily oral medicine comprising 50mg of non-structural protein 5A (NS5A) replication complex inhibitor elbasvir and 100mg of NS3/4A protease inhibitor grazoprevir.
Ocrevus (ocrelizumab) for the Treatment of Multiple Sclerosis
Developed by Genentech, Ocrevus (ocrelizumab) is indicated for the treatment of relapsing multiple sclerosis (MS) and primary progressive MS.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.